Keywords: Eli Lilly, Transition Therapeutics, Licensing, Diabetes compounds

Eli Lilly sells rights to diabetes compounds to Transition Therapeutics

Article | 04 March 2010

Print This

Canada’s Transition Therapeutics says that it has acquired the rights to a series of preclinical compounds from US drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in